Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Hampton, David W ^a   Serio, Andrea ^a   Pryce, Gareth ^b   Al Izki, Sarah ^b   Franklin, Robin JM ^c   Giovannoni, Gavin ^b   Baker, David ^b   Chandran, Siddharthan ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Experimental autoimmune encephalomyelitis; Gliosis; Multiple sclerosis; Neurodegeneration; Remyelination

Indexed keywords

EID: 85005878483     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-84     Document Type: Article

References (39)

1. Compston A, Coles A: Multiple sclerosis. Lancet 2008, 372: 1502-1517. 10.1016/S0140-6736(08)61620-7
2. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M: Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006, 5: 343-354. 10.1016/S1474-4422(06)70410-0
3. Confavreux C, Vukusic S: Age at disability milestones in multiple sclerosis. Brain 2006, 129: 595-605. 10.1093/brain/awh714
4. Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129: 606-616. 10.1093/brain/awl007
5. Bjartmar C, Trapp BD: Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001, 14: 271-278. 10.1097/00019052-200106000-00003
6. Bjartmar C, Trapp BD: Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 2003, 5: 157-164. 10.1007/BF03033380
7. Dutta R, Trapp BD: Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007, 68: S22-S31. 10.1212/01.wnl.0000275229.13012.32
8. Foote AK, Blakemore WF: Inflammation stimulates remyelination in areas of chronic demyelination. Brain 2005, 128: 528-539. 10.1093/brain/awh417
9. Ruckh JM, Zhao JW, Shadrach JL, van Wijngaarden P, Rao TN, Wagers AJ, et al.: Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell 2012, 10: 96-103. 10.1016/j.stem.2011.11.019
10. Setzu A, Lathia JD, Zhao C, Wells K, Rao MS, Ffrench-Constant C, et al.: Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia 2006, 54: 297-303. 10.1002/glia.20371
11. Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, et al.: Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008, 131: 1736-1748. 10.1093/brain/awn119
12. Baker D, O'Neill JK, Gschmeissner SE, Wilcox CE, Butter C, Turk JL: Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 1990, 28: 261-270. 10.1016/0165-5728(90)90019-J
13. Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, et al.: An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol 2008, 201-202: 200-211.
14. Ludwin SK, Sternberger NH: An immunohistochemical study of myelin proteins during remyelination in the central nervous system. Acta Neuropathol 1984,63(3):240-248. 10.1007/BF00685250
15. Manrique-Hoyos N, Jürgens T, Grønborg M, Kreutzfeldt M, Schedensack M, Kuhlmann T, Schrick C, Brück W, Urlaub H, Simons M, Merkler D: Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann Neurol 2012, 71: 227-244. 10.1002/ana.22681
16. Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G: Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol 2003, 138: 45-48. 10.1016/S0165-5728(03)00092-4
17. Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, et al.: Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J Neuroimmunol 2005, 165: 41-52. 10.1016/j.jneuroim.2005.04.009
18. Smith PA, Morris-Downes M, Heijmans N, Pryce G, Arter E, O'Neill JK, et al.: Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice. J Neuroimmunol 2005, 164: 76-84. 10.1016/j.jneuroim.2005.04.006
19. Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D: Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult Scler 2011, 17: 939-948. 10.1177/1352458511400476
20. Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D: Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult Scler Rel Dis 2012, 1: 29-38.
21. Hampton DW, Seitz A, Chen P, Heber-Katz E, Fawcett JW: Altered CNS response to injury in the MRL/MpJ mouse. Neuroscience 2004, 127: 821-832. 10.1016/j.neuroscience.2004.05.057
22. Hampton DW, Steeves JD, Fawcett JW, Ramer MS: Spinally upregulated noggin suppresses axonal and dendritic plasticity following dorsal rhizotomy. Exp Neuro 2007, 204: 366-379. 10.1016/j.expneurol.2006.11.017
23. Scott AL, Borisoff JF, Ramer MS: Deafferentation and neurotrophin-mediated intraspinal sprouting: a central role for the p75 neurotrophin receptor. Eur J Neurosci 2005, 21: 81-92. 10.1111/j.1460-9568.2004.03838.x
24. Willis WD, Coggeshall RE: Sensory Mechanisms of the Spinal Cord. New York: Kluwer Academic/Plenum Publishers; 2004.
25. Jackson SJ, Lee J, Nikodemova M, Fabry Z, Duncan ID: Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. J Neuropathol Exp Neurol 2009, 68: 616-625. 10.1097/NEN.0b013e3181a41d23
26. Hazama GI, Yasuhara O, Morita H, Aimi Y, Tooyama I, Kimura H: Mouse brain IgG-like immunoreactivity: strain-specific occurrence in microglia and biochemical identification of IgG. J Comp Neurol 2005, 492: 234-249. 10.1002/cne.20710
27. Szalai AJ, Barnum SR: Fc receptors and the common gamma-chain in experimental autoimmune encephalomyelitis. J Neurosci Res 2004, 75: 597-602. 10.1002/jnr.20023
28. Readnower RD, Chavko M, Adeeb S, Conroy MD, Pauly JR, McCarron RM, et al.: Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury. J Neurosci Res 2010, 88: 3530-3539. 10.1002/jnr.22510
29. Ryu JK, McLarnon JG: Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol 2006, 198: 552-557. 10.1016/j.expneurol.2005.12.016
30. Schirmer L, Albert M, Buss A, Schulz-Schaeffer WJ, Antel JP, Brück W, et al.: Substantial early, but nonprogressive neuronal loss in multiple sclerosis (MS) spinal cord. Ann Neurol 2009,66(5):698-704. 10.1002/ana.21799
31. Vogt J, Paul F, Aktas O, Müller-Wielsch K, Dörr J, Dörr S, et al.: Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol 2009,66(3):310-322. 10.1002/ana.21719
32. Coles A, Deans J, Compston A: Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004, 106: 270-274. 10.1016/j.clineuro.2004.02.013
33. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al.: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359: 1786-1801.
34. Bruce CC, Zhao C, Franklin RJ: Remyelination - An effective means of neuroprotection. Horm Behav 2010,57(1):56-62. 10.1016/j.yhbeh.2009.06.004
35. Franklin RJ, Ffrench-Constant C, Edgar JM, Smith KJ: Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 2012,8(11):624-634. 10.1038/nrneurol.2012.200
36. Irvine KA, Blakemore WF: Remyelination protects axons from demyelination- associated axon degeneration. Brain 2008, 131: 1464-1477. 10.1093/brain/awn080
37. Hampton DW, Innes N, Merkler D, Zhao C, Franklin RJ, Chandran S: Focal immune-mediated white matter demyelination reveals an age-associated increase in axonal vulnerability and decreased remyelination efficiency. Am J Pathol 2012, 180: 1897-1905. 10.1016/j.ajpath.2012.01.018
38. Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, Casaccia-Bonnefil P: Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 2008,11(9):1024-1034. 10.1038/nn.2172
39. Shields S, Gilson J, Blakemore W, Franklin R: Remyelination occurs as extensively but more slowly in old rats compared to young rats following fliotoxin-induced CNS demyelination. Glia 1999,28(1):77-83. 10.1002/(SICI)1098-1136(199910)28:1<77::AID-GLIA9>3.0.CO;2-F